Literature DB >> 17916319

Central retinal vein occlusion case-control study.

Hideki Koizumi1, Daniela C Ferrara, Claudia Bruè, Richard F Spaide.   

Abstract

PURPOSE: To investigate risk factors for central retinal vein occlusion (CRVO).
DESIGN: Retrospective case-control study.
METHODS: Consecutive patients with CRVO examined from July 1, 2005 through July 31, 2006 were compared with an historical gender- and age-matched control group of patients with ocular problems other than vascular occlusive disease from the same referral practice. Risk factors for CRVO were evaluated.
RESULTS: The 144 patients in the CRVO group, 87 males and 57 females, had a mean age of 69.6 years (+/-13.6 years). CRVO was associated with hypertension (P < .001), diabetes mellitus (P = .047), glaucoma (P < .001), atrial fibrillation (P = .036), angiotensin-converting enzyme inhibitor use (P = .022), aspirin use (P < .001), and warfarin use (P = .011) by univariate analyses. Postmenopausal estrogen use was more common among women in the control group (P = .029). Multivariate logistic regression found the independent predictors for CRVO to be: glaucoma (adjusted odds ratio [OR], 4.75; P < .001), aspirin use (adjusted OR, 2.66; P = .001), and warfarin use (adjusted OR, 3.34; P = .005).
CONCLUSIONS: We found many of the same risk factors previously identified for CRVO by other studies, but we identified both aspirin and warfarin use to be independent risk factors for CRVO. Although these findings suggest the vasculopathic and prothrombotic risks in some patients may not be addressed adequately by antithrombotic therapy, they also suggest that the pathogenesis of CRVO may be more complicated than just the development of a primary thrombus within the vein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916319     DOI: 10.1016/j.ajo.2007.07.036

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  22 in total

1.  [Arguments for prophylactic therapy of ocular hypertension].

Authors:  J Wahl
Journal:  Ophthalmologe       Date:  2011-11       Impact factor: 1.059

2.  Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants.

Authors:  Sohan Singh Hayreh; Patricia A Podhajsky; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2011-06-24       Impact factor: 12.079

3.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

4.  Novel Association between Opioid Use and Increased Risk of Retinal Vein Occlusion Using the National Institutes of Health All of Us Research Program.

Authors:  John J McDermott; Terrence C Lee; Alison X Chan; Gordon Y Ye; Bita Shahrvini; Bharanidharan Radha Saseendrakumar; Henry Ferreyra; Eric Nudleman; Sally L Baxter
Journal:  Ophthalmol Sci       Date:  2021-12-20

5.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

6.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 7.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

8.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

9.  Inflammation in retinal vein occlusion.

Authors:  Avnish Deobhakta; Louis K Chang
Journal:  Int J Inflam       Date:  2013-04-03

10.  Central retinal vein occlusion and pseudoexfoliation syndrome.

Authors:  Dimitrios Karagiannis; Georgios A Kontadakis; Nektarios E Klados; Ioannis Tsoumpris; Artemios S Kandarakis; Efstratios A Parikakis; Ilias Georgalas; Miltiadis K Tsilimbaris
Journal:  Clin Interv Aging       Date:  2015-05-20       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.